CG Oncology

CGON

Market cap $5.9B

69.89 USD

+0.01

0.01%

At close Updated Apr 23, 4:00 PM EDT

Pre-market

After hours

69.58

-0.31

0.44%

1 day

0.01%

5 days

3.37%

1 month

7.59%

3 months

29.88%

6 months

66.48%

Year to date

67.24%

1 year

237.14%

5 years

88.03%

10 years

88.03%

About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Employees: 142

Healthcare Biotechnology